| Literature DB >> 32444699 |
Guido Primiano1,2, Edoardo Abed3, Giovanni Corbo3, Angelo Maria Minnella4,3, Serenella Servidei5,3, Catello Vollono5,3, Maria Cristina Savastano4,3, Benedetto Falsini4,3.
Abstract
The high-energy demands of the retina are thought to contribute to its particular vulnerability to mitochondrial dysfunction. Photoreceptors are the cells with the higher oxygen consumption within the retina, and among these, the cones contain more mitochondria and have a higher energy demand than rods. A cohort of twenty-two patients with genetically-defined mitochondrial diseases (MDs) were enrolled to determine if the macula is functionally and anatomically impaired in these metabolic disorders. Visual acuity and fERG amplitude of patients with primary mitochondrial dysfunction were reduced compared to controls. Furthermore, SD-OCT layer segmentation showed a reduction of retinal and outer nuclear layer (ONL) volume in the macula of the patients. fERG amplitude showed a positive correlation with both ONL volume and thickness. A negative relationship was noted between fERG amplitude and disease severity assessed with Newcastle Mitochondrial Disease Adult Scale. In conclusion, MDs are associated with functional and anatomical alteration of macular cone system, characterized by its strong correlation with clinical disease severity suggesting a role as a potential biomarker of primary mitochondrial disorders.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32444699 PMCID: PMC7244507 DOI: 10.1038/s41598-020-65482-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographics and clinical data of patients with mitochondrial disease.
| Patient | Age | Sex | Phenotype | Genotype | BCVA RE | BCVA LE | fERG RE (μV) | fERG LE (μV) | Goldmann RE V/4e isopter | Goldmann LE V/4e isopter | NMDAS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 54 | M | PEO | sDel mtDNA | 0.22 | 0.15 | 0.08 | 0.15 | 110° | 125° | 34 |
| 2 | 44 | M | PEO | mDel (POLG1, c.2864A>G) | 0.10 | 0.22 | 0.18 | 1.01 | 140° | 145° | 22 |
| 3 | 42 | F | MERRF | m.8356T>C | 0.22 | 0.22 | 0.93 | 1.24 | 120° | 132° | 20 |
| 4 | 69 | M | PEO | sDel mtDNA | 0 | 0 | 0.94 | 1.51 | 122° | 123° | 13 |
| 5 | 74 | F | PEO | sDel mtDNA | 0.10 | 0 | 0.69 | 0.25 | 113° | 110° | 21 |
| 6 | 42 | F | MERRF | m.8344A>G | 0 | 0 | 1.08 | 0.87 | 130° | 127° | 17 |
| 7 | 60 | M | MERRF | m.8344A>G | 0 | 0 | 1.31 | 1.43 | 128° | 120° | 23 |
| 8 | 42 | M | MNGIE | mDel (c.925C > G exon 7 and c.1231_1243del exon 9 TYMP) | 0 | 0 | 0.29 | 0.15 | 105° | 110° | 25 |
| 9 | 62 | F | PEO | mDel mtDNA | 0 | 0 | 0.46 | 0.22 | 133° | 141° | 20 |
| 10 | 50 | F | PEO | mDel mtDNA | 0 | 0 | 1.57 | 1.74 | 150° | 150° | 9 |
| 11 | 44 | F | PEO | sDel mtDNA | 0 | 0 | 0.73 | 0.85 | 135° | 140° | 18 |
| 12 | 75 | M | PEO | sDel mtDNA | 0 | 0 | 1.85 | 1.33 | 120° | 115° | 15 |
| 13 | 31 | F | PEO | sDel mtDNA | 0.15 | 0.15 | 0.53 | 1.27 | 105° | 97° | 22 |
| 14 | 52 | M | PEO | mDel mtDNA | 0 | 0 | 0.64 | 0.76 | 130° | 138° | 17 |
| 15 | 63 | F | PEO | mDel mtDNA | 0.22 | 0.15 | 0.29 | 0.40 | 122° | 105° | 25 |
| 16 | 22 | M | MNGIE | mDel (c.977G>A exon 8 and c.215-12_222del exon 3 TYMP) | 0 | 0 | 1.17 | 1.24 | 112° | 110° | 17 |
| 17 | 64 | F | MERRF | m.8344A>G | 0.05 | 0.05 | 0.21 | 0.17 | 105° | 100° | 26 |
| 18 | 25 | F | PEO | m.3243A>G | 0.05 | 0.05 | 0.65 | 0.35 | 115° | 120° | 25 |
| 19 | 44 | M | MERRF | m.8344A>G | 0 | 0 | 1.25 | 1.29 | 130° | 112° | 8 |
| 20 | 41 | M | MNGIE | mDel (c.925C > G exon 7 and c.1231_1243del exon 9 TYMP) | 0 | 0 | 0.18 | 0.43 | 123° | 131° | 22 |
| 21 | 52 | F | PEO | mDel (POLG1, c.1943C > G and c.2243 G > C) | 0 | 0 | 0.11 | 0.45 | 112° | 114° | 24 |
| 22 | 51 | F | MELAS | m.3243A>G | 0 | 0 | 1.23 | 1.26 | 124° | 118° | 21 |
(NMDAS: Newcastle Mitochondrial Disease Adult Scale).
Figure 1Box plot comparing mean ± SE BCVA (A) and fERG 1F amplitude (B) in patients with mitochondrial disease and control group *p < 0.01, **p < 0.0001; Box plot comparing mean ± SE macular (C) and ONL (D) volume in patients with mitochondrial diseases (mt disease) and control group *p < 0.05, **p < 0.001.
Figure 2Scatterplot showing the positive correlation between fERG 1F amplitude and ONL volume (A) and thickness (B); scatterplot showing the inverse correlation between fERG 1F amplitude and Newcastle scale score in patients with mitochondrial disease (mt disease) (C).
Comparison of thickness and volume of the entire retina and of individual retinal layers between healthy subjects and patients with mitochondrial disease (mean ± SD).
| RT | RNFL | GCL | IPL | INL | OPL | ONL | IRL | PR | RPE | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mitochondrial disease | 304 ± 6 | 13.3 ± 0.9 | 19.5 ± 3.7 | 23.7 ± 2.1 | 23.3 ± 2.7 | 25.9 ± 1.3 | 84.8 ± 3.6 | 190.3 ± 8.7 | 88.2 ± 1.2 | 16.4 ± 3.8 |
| Controls | 313 ± 4 | 13.4 ± 0.3 | 18.3 ± 1.5 | 21.3 ± 0.9 | 21.1 ± 1.4 | 25.5 ± 1.1 | 93.3 ± 2.9 | 191.1 ± 4.5 | 87.3 ± 0.9 | 17.8 ± 3.2 |
| P | 0.21 | 0.96 | 0.77 | 0.32 | 0.42 | 0.82 | 0.08 | 0.94 | 0.57 | 0.33 |
| Mitochondrial disease | 0.73 ± 0.02 | 0.010 ± 0.0 | 0.016 ± 0.002 | 0.019 ± 0.002 | 0.018 ± 0.002 | 0.019 ± 0.001 | 0.067 ± 0.002 | 0.14 ± 0.004 | 0.068 ± 0011 | 0.014 ± 0.002 |
| Controls | 0.89 ± 0.03 | 0.011 ± 0.0 | 0.013 ± 0.001 | 0.018 ± 0.001 | 0.018 ± 0.001 | 0.020 ± 0.0 | 0.074 ± 0.002 | 0.15 ± 0.013 | 0.069 ± 0.001 | 0.015 ± 0.002 |
| P | 0.0002 | 0.34 | 0.40 | 0.53 | 0.96 | 0.34 | 0.03 | 0.30 | 0.52 | 0.22 |
Figure 3Representative example of the left eye of a patient with MELAS. Infrared (A), Autofluorescence (B), SD-OCT B-scan centered at the fovea with EDI mode (C); automated segmentation details of Spectralis (D). ONL highlighted in yellow for better visualization; IR and AF did not show changes; full macular volume and ONL volume decreased in SD-OCT analysis for eye’s MELAS patient (E). Inner limiting membrane (ILM), retinal nervous fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), external limiting membrane (ELM), photoreceptor inner layer (PR1), photoreceptor outer layer (PR2), retinal pigment epithelium (RPE), Bruchs membrane (BM).